Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?
de Lorgeril
Michel
M
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D019821:Simvastatin; D000069438:Ezetimibe